Krebs Biochemicals & Industries Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022
For the six months, sales was INR 315.83 million compared to INR 187.36 million a year ago. Revenue was INR 319.87 million compared to INR 188.97 million a year ago. Net loss was INR 121.98 million compared to INR 202.72 million a year ago. Basic loss per share from continuing operations was INR 5.66 compared to INR 9.42 a year ago. Diluted loss per share from continuing operations was INR 5.66 compared to INR 9.42 a year ago.